CSL Breaks Ground on $1.5B Illinois Expansion, Boosting US Medical Supply Chain

KANKAKEE, IL – March 09, 2026 – Global biopharma leader CSL today launched a monumental $1.5 billion expansion of its manufacturing facility in Kankakee, a move poised to significantly bolster the U.S. supply of critical plasma-derived therapies while injecting hundreds of high-skilled jobs into the regional economy. The groundbreaking ceremony, attended by Illinois Governor JB Pritzker and other dignitaries, marks a pivotal moment for both the company and the state, reinforcing Illinois's growing reputation as a hub for life sciences manufacturing.

The investment is a cornerstone of CSL's global growth strategy and its commitment to strengthening its American manufacturing footprint. This project alone will create at least 300 new, permanent pharmaceutical roles and an estimated 800 construction jobs, providing a substantial economic stimulus to a region that has faced economic headwinds. The expansion builds on more than $3 billion CSL has already invested in its U.S. operations since 2018, which has added over 6,500 jobs nationwide.

"Illinois is leading the way in life sciences manufacturing, and CSL's $1.5 billion investment is a powerful vote of confidence in our state," said Governor JB Pritzker. "This expansion will create hundreds of good-paying jobs and strengthen domestic supply chains for critical therapies. We're proud to partner with CSL as they expand their footprint and deepen their commitment to communities across our state."

A Billion-Dollar Boost for the Local Economy

For Kankakee County, a region with a 2025 unemployment rate of 6.7%, the economic impact of CSL's expansion cannot be overstated. The infusion of 300 new, highly skilled permanent positions at a facility that already employs over 1,200 people represents a significant opportunity for local workforce development and economic stability. The average median household income in the county stood at $68,325 in 2023, and the addition of well-paying pharmaceutical jobs is expected to have a positive ripple effect throughout the community.

Local officials celebrated the announcement as a landmark achievement resulting from a long-standing partnership. "This is exciting news on several fronts. First and foremost, the life-saving therapies CSL produces change lives," said Illinois State Senator Patrick Joyce. "For the region's economy, this is great news for the 300 good paying jobs and the investment in our local community through infrastructure improvements."

The collaboration extends beyond job creation. The project was facilitated by years of discussion and planning between CSL and local government to address infrastructure needs, including the provision of additional sewer capacity and a dedicated sewer line to support the expanded operations. This public-private partnership demonstrates a shared commitment to fostering long-term industrial growth.

"I am thrilled CSL made the decision to expand in Illinois, right here in the 79th district," added Illinois State Representative Jackie Haas. "CSL has always been a wonderful partner to this community. I can't wait to see the positive impacts this expansion will have on our entire region!"

Meeting a Critical and Growing Patient Need

The driving force behind this massive investment is the soaring global demand for plasma-derived therapies (PDTs). These unique medicines are indispensable for thousands of people living with rare, chronic, and life-threatening conditions such as primary immunodeficiency (PI), hemophilia, and hereditary angioedema. The global market for these therapies, valued at over $16.8 billion in 2022, is projected to nearly double to over $32 billion by 2032.

Unlike conventional pharmaceuticals, PDTs cannot be synthesized in a lab. They are derived from human plasma, a component of blood that must be donated. Manufacturing is a complex, months-long process involving rigorous testing, purification, and formulation. Treating a single patient for one year can require plasma from hundreds or even thousands of individual donations, making a secure and efficient supply chain paramount.

Patient advocates underscore the life-or-death importance of such investments. "For people living with rare diseases like primary immunodeficiency, consistent access to treatment is the foundation that lets them plan their days and their futures," said Jorey Berry, president and CEO of the Immunodeficiency Deficiency Foundation. "Manufacturing plasma-derived therapies is a lengthy and complex process, and maintaining reliable supply is an ongoing challenge. This expansion in Kankakee is a powerful sign that patients' hopes are truly being prioritized."

The Technological Edge: Horizon 2

At the heart of the Kankakee expansion, which is expected to be fully operational by 2031, is CSL's proprietary 'Horizon 2' manufacturing process. This patented, next-generation technology represents a significant leap forward in production efficiency. It is designed to substantially increase the yield of immunoglobulin—a key protein used in many therapies—from the same amount of donated plasma.

"This site expansion marks an important step forward in increasing efficiency by incorporating new, innovative manufacturing processes and technology into how we produce the plasma-based medicines needed by so many people," explained Mary Oates, CSL's Executive Vice President and Chief Operating Officer. "These improvements will increase protein yield from each gram of plasma collected, strengthening Kankakee's role as a vital site in our global network."

By maximizing the output from each precious donation, the Horizon 2 process directly addresses the core challenge of the plasma industry: meeting rising demand with a finite resource. This technological advantage is crucial for ensuring a sustainable and reliable supply of therapies for a growing patient population.

A Blueprint for American Biomanufacturing

CSL's investment in Kankakee aligns with a broader national imperative to strengthen the domestic biopharmaceutical supply chain. Recent federal policies, including executive orders and proposed legislation like the 'Biomanufacturing Excellence Act of 2025,' are aimed at reducing the nation's reliance on foreign manufacturing for critical medicines and enhancing national health security.

This expansion serves as a real-world example of that policy in action. By significantly increasing domestic production capacity for essential therapies, the Kankakee facility will help insulate the U.S. from global supply chain disruptions and ensure that American patients have access to the treatments they need.

"Manufacturing makes the world a better place to live, and CSL is a perfect example of the impact this industry has at home and abroad," stated Mark Denzler, president & CEO of the Illinois Manufacturers' Association. "This expansion is a win for Illinois and the many people across the globe who rely on the groundbreaking work of CSL."

John Conrad, President and CEO of the Illinois Biotechnology Innovation Organization (iBIO), echoed this sentiment, noting, "CSL's investment underscores the critical role Illinois plays in producing the life-saving therapies patients depend on. Expansions like this help ensure patients around the world have access to the innovative treatments they need."

As construction begins, the project symbolizes a multifaceted victory—a promise of hope for patients, a catalyst for regional economic renewal, and a strategic reinforcement of America's domestic manufacturing capabilities.